In anticipation of a bad inflation report on Thursday when the CPI numbers come out, the markets all dropped except for the surge in the Nasdaq that went on most of the day but then dropped to close almost even. The meme stocks continue to go crazy with heavy shorting. I remain suspicious that this must be illegal and I await the results of the investigation. Volume was again above the 4-week average at a very vigorous 11.5 billion. 

WED  JUNE 9, 2021  4:37 PM 

U.S. stocks end lower ahead of inflation report

By Stephen Culp

DJ: 34,599.82  -30.42          NAS: 13,924.91  +43.19        S&P: 4,227.26  +0.74       6/8

DJ: 34,447.14  -152.68        NAS: 13,911.75  -13.16         S&P: 4,219.55  -7.71        6/9 

NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.  The retail “meme stock” craze continued unabated.  All three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.

“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”  Heavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.

Reddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.  However, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath & Beyond closed lower.  Retail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.  “It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”  “I don’t think you should read too much regarding the broader market.”  GameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.

U.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.  Industrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.  Washington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.  Even so, the Philadelphia SE Semiconductor index slipped 0.4%.

The Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.

The Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.  Among the 11 major sectors in the S&P 500, healthcare gained the most.

Benchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.

Campbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%. Pfizer Inc gained 2.5% after the Biden administration unveiled plans to donate 500 COVID-19 doses to about 100 countries over the next two years, according to a Washington Post report.  Drugmaker Merck & Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.

Declining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.  The S&P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.

Volume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.